Home » Newsletters » BioWorld Asia

BioWorld Asia

April 24, 2000

View Archived Issues

Antisoma Stock Takes Hit Following Independent Study

CeNeS Buying Cambridge Neuro In All-Stock Deal Valued At $44M

Study Of Rare Disorder Provides Clues For New Cancer Therapies

French Researchers Say There Are Only About 30,000 Genes

Oxford GlycoSciences Issued Broad Patent On Proteomics

NicOx Reports Early Phase II Results, Starts Phase I Study

Watson, Arntzen Among Those Adding Input To Israeli Biotech

SkyePharma Changes Strategy, Plans More Development Work

ExonHit, Collaborators Identify Markers Linked To Hypoxia

Queensland Group Develops Genetic Test For Skin Cancer

Other News To Note

United Nations Takes Step Toward Labeling GM Food

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...